KSKarin Söderkvist

Karin Söderkvist

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Karin Söderkvist has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fracture risk and initiation of bone‐specific drug therapy following radical cystectomy with urinary diversion

    by Mieke Van Hemelrijck, Lars Holmberg, Hans Garmo, Truls Gårdmark, Henrik Kjölhede, Tomas Jerlström, Karin Söderkvist, Anders Ullén, Fredrik Liedberg, Karl Michaëlsson, et al.

    Objectives: To assess the risk of fractures among patients with bladder cancer who underwent radical cystectomy (RC) with urinary diversion (UD), compared with matched referents from the general population. Patients/Subjects and Methods: We identified 2908 patients who underwent RC between 2011 and 2019, and 13 669 matched referents in a nationwide, register‐based Swedish cohort study. Outcomes were femoral fracture, any fracture, and initiation of bone‐specific drug therapy (BDT). Cumulative incidence was estimated using competing‐risk analyses, and hazard ratios (HRs) were derived from multivariable Cox models stratified by sex. Additional analyses were conducted among patients with muscle‐invasive bladder cancer treated with curative radiotherapy ( n = 328). Results: Compared to referents, RC with UD was associated with a higher cumulative incidence of fractures. Women had an increased risk of femoral fracture (HR 1.97, 95% confidence interval [CI] 1.25–3.10) and any fracture (HR 2.06, 95% CI 1.54–2.76), while men had an increased risk of any fracture (HR 1.51, 95% CI 1.22–1.88). No association was observed for initiation of BDT in either sex. In the additional cohort, men treated with radiotherapy had an increased risk of any fracture (HR 2.14, 95% CI 1.26–3.62), whereas estimates for women were imprecise. Conclusion: Patients undergoing RC with UD experienced increased fracture risks, particularly women. Additional analyses suggest that fracture risk may be influenced by factors related to both bladder cancer and its treatment, although the strongest and most consistent associations were observed following RC with UD. These findings support increased attention to bone health in these patients.

  • Open Access

    Outcomes of pelvic radiotherapy with boost strategies in high nodal-risk prostate cancer: A phase 2 prospective trial

    by Camilla Thellenberg Karlsson, Kristina Notstam, Björn Tavelin, Kristina Lundqvist, Per Fransson, Karin Söderkvist

  • Open Access

    Automatic segmentation of the urethra and prostate zones with deep learning on T2-weighted magnetic resonance imaging

    by William Holmlund, Attila Simkó, Karin Söderkvist, Péter Palásti, Szilvia Tótin, Kamilla Kalmár, Zsófia Domoki, Zsuzsanna Fejes, Tamás Z. Kincses, Patrik Brynolfsson, et al.


  • Open Access

    Ultra-hypofractionated radiotherapy with focal boost for high-risk localized prostate cancer (HYPO-RT-PC-boost): in silico evaluation with histological reference

    by Erik Nilsson, Anneli Nilsson, Joakim Jonsson, Kristina Sandgren, Josefine Grefve, Jan Axelsson, Angsana K. Lindberg, Karin Söderkvist, Camilla T. Karlsson, Björn Zackrisson, et al.

    Background and purpose: The study aims to evaluate dosimetric properties of hypofractionated treatment plans integrating focal boost, using registered whole-mount histopathology (WMHP) as reference standard. Methods: Fifteen men from the PAMP trial (EudraCT: 2015-005046-55) were included. Participants had ≥ 1 ISUP Grade group ≥ 4 lesion and underwent [68Ga]prostate-specific membrane antigen (PSMA) positron emission tomography/multiparametric magnetic resonance imaging (PET/mpMRI) and [11C]Acetate-PET/computed tomography before radical prostatectomy. Four radiation oncologists delineated gross tumor volumes (GTVs) on PSMA-PET/mpMRI. Sixty treatment plans were optimized, one per GTV and patient. Prostate planning target volumes were prescribed 42.7 Gy in seven fractions, with a simultaneous GTV boost up to 49.0 Gy, prioritizing organs at risk (OARs). Digital WMHP provided Gleason grading and was co-registered with in-vivo imaging. Target coverage for GTVs and voxels sharing Gleason patterns (GPs) was assessed via dose-volume histogram (DVH) analysis. Interobserver agreement in GTV-delineations was quantified with Fleiss’ kappa. Results: The median GTV dose per plan (D50) ranged from 48.3 to 49.1 Gy. For voxels with the highest GP, D50 was 42.9–49.2 Gy, exceeding 47.2 Gy in all except one plan. In lowest pattern voxels, D50 was 42.5–49.3 Gy, and below 43.4 Gy in over half the plans. Significant positive correlations between Fleiss’ kappa and DVH parameters appeared only for GP 5 regions, specifically for Fleiss’ kappa and D50 for two observers and the average D50 across observers. Interpretation: The histologically confirmed tumor was only partially boosted. Regions with more aggressive disease received better coverage. These findings provide a rational for prioritizing OARs in treatment planning.


  • Open Access

    Waiting time in diagnosis and extirpative surgery and association with survival and stage progression in upper tract urothelial carcinomas

    by Fredrik Liedberg, Oskar Hagberg, Christel Häggström, Firas Aljabery, Truls Gårdmark, Staffan Jahnson, Tomas Jerlström, Viveka Ströck, Karin Söderkvist, Anders Ullén, et al.

    Objectives: To investigate the association between waiting time and outcomes in patients with upper tract urothelial carcinomas (UTUC).Patients and methods: We studied a population‐based cohort of 858 patients in BladderBaSe 2.0 subjected to extirpative surgery for UTUC 2015–2019 in Sweden. Diagnostic waiting time (from referral to diagnosis, reference <1 week), treatment waiting time (from diagnosis to surgery, reference <5 weeks) and total waiting time (reference 4 weeks was associated with stage progression (OR 2.44 [95% CI 1.00–5.95]), and in patients with UTUC in the ureter, a treatment waiting time between 5 and 10 weeks was associated to worse DSS (HR 2.85 (95% CI 1.03–7.89).Conclusions: In general, shorter care pathways were linked to beneficial survival estimates, yet some estimates may be influenced by selection bias due to prioritizing short waiting times for patients with advanced and/or overt symptomatic tumours. Stage progression with increased waiting time may indicate an underlying causal mechanism.


  • Open Access

    Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging

    by Josefine Grefve, Karin Söderkvist, Adalsteinn Gunnlaugsson, Kristina Sandgren, Joakim Jonsson, Angsana Keeratijarut Lindberg, Erik Nilsson, Jan Axelsson, Anders Bergh, Björn Zackrisson, et al.


  • Open Access

    Diagnostic pathways and treatment strategies in upper tract urothelial carcinoma in Sweden between 2015 and 2021: a population-based survey

    by Fredrik Liedberg, Oskar Hagberg, Firas Aljabery, Truls Gårdmark, Staffan Jahnson, Tomas Jerlström, Viveka Ströck, Karin Söderkvist, Anders Ullén, Johannes Bobjer

    Objective: To report national data on diagnostics and treatment of upper tract urothelial carcinoma (UTUC) from the Swedish National Registry of Urinary Bladder Cancer (SNRUBC). Patients and methods: Data from 2015 to 2021 were retrieved, and descriptive analyses were performed regarding incidence, diagnostic modalities, preoperative tumor staging, quality indicators for treatment including the use of standardized care pathways (SCP) and multidisciplinary tumor boards (MDTB). Time trends were explored for the study period. Results: Registrations included 1,213 patients with renal pelvic cancer and 911 patients with ureteric cancer with a median age of 74 (interquartile range [IQR] 70–77) and 75 (IQR 71–78) years, respectively. Incidence rates of UTUC were stable, as were proportions of curative treatment intent. Median number of days from referral to treatment was 76 (IQR 57–99) and 90 (IQR 72–118) days, respectively, for tumors of the renal pelvis and ureter, which remained unchanged after introduction of SCP in 2016. Noticeable trends included stable use of kidney-sparing surgery and increased use of MDTB. For radical nephroureterectomy (RNU), robot-assisted technique usage increased even for non-organ-confined tumors (cT3-4) and in one out of three patients undergoing RNU a bladder cuff excision was not registered. Conclusions: The population-based SNRUBC with high coverage contributes to the knowledge about UTUC with granular and generalizable data. The present study reveals a high proportion of patients not subjected to curatively intended treatment and suggests unmet needs to shorten lead times to treatment and use of bladder cuff excision when performing radical surgery for UTUC in Sweden.


  • Open Access

    The grade of individual prostate cancer lesions predicted by magnetic resonance imaging and positron emission tomography

    by Erik Nilsson, Kristina Sandgren, Josefine Grefve, Joakim Jonsson, Jan Axelsson, Angsana Keeratijarut Lindberg, Karin Söderkvist, Camilla Thellenberg Karlsson, Anders Widmark, Lennart Blomqvist, et al.

    Background: Multiparametric magnetic resonance imaging (mpMRI) and positron emission tomography (PET) are widely used for the management of prostate cancer (PCa). However, how these modalities complement each other in PCa risk stratification is still largely unknown. We aim to provide insights into the potential of mpMRI and PET for PCa risk stratification. Methods: We analyzed data from 55 consecutive patients with elevated prostate-specific antigen and biopsy-proven PCa enrolled in a prospective study between December 2016 and December 2019. [68Ga]PSMA-11 PET (PSMA-PET), [11C]Acetate PET (Acetate-PET) and mpMRI were co-registered with whole-mount histopathology. Lower- and higher-grade lesions were defined by International Society of Urological Pathology (ISUP) grade groups (IGG). We used PET and mpMRI data to differentiate between grades in two cases: IGG 3 vs. IGG 2 (case 1) and IGG ≥ 3 vs. IGG ≤ 2 (case 2). The performance was evaluated by receiver operating characteristic (ROC) analysis. Results: We find that the maximum standardized uptake value (SUVmax) for PSMA-PET achieves the highest area under the ROC curve (AUC), with AUCs of 0.72 (case 1) and 0.79 (case 2). Combining the volume transfer constant, apparent diffusion coefficient and T2-weighted images (each normalized to non-malignant prostatic tissue) results in AUCs of 0.70 (case 1) and 0.70 (case 2). Adding PSMA-SUVmax increases the AUCs by 0.09 (p < 0.01) and 0.12 (p < 0.01), respectively. Conclusions: By co-registering whole-mount histopathology and in-vivo imaging we show that mpMRI and PET can distinguish between lower- and higher-grade prostate cancer, using partially discriminative cut-off values.


  • Open Access

    Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era

    by Karin Holmsten, Johanna Eknert, Elisabeth Öfverholm, Dimitrios Papantoniou, Faith Jawdat, Ingrida Verbiéné, Anna Laurell, Elin Jänes, Johan Sandzén, Elzbieta Wojtyna-Dziedzic, et al.


  • Open Access

    Short term outcomes after robot assisted and open cystectomy - A nation-wide population-based study

    by Oskar Bergengren, Alexej Belozerov, Anna Bill-Axelson, Hans Garmo, Oskar Hagberg, Firas Aljabery, Truls Gårdmark, Staffan Jahnson, Tomas Jerlström, Per-Uno Malmström, et al.